INVO Bioscience Reports First Quarter 2022 Financial Results

Rhea-AI Summary

INVO Bioscience, a fertility-focused company, reported Q1 2022 revenue of approximately $0.2 million, a 76% decline from $0.7 million in Q1 2021, due to a one-time bulk order in the prior year. Gross margins decreased to 60% from 91% year-over-year. Despite the revenue dip, patient inquiries increased by 40% across INVO Centers, signaling potential growth. The company plans to expand with new centers and signed an exclusive agreement with Onesky for distribution in China. Cash as of March 31, 2022, stood at $3.8 million.

Positive

• 40% increase in patient inquiries and consultations at INVO Centers.
• Plans to open new INVO Centers in Tampa and Kansas City, enhancing reach.
• Signed exclusive distribution agreement with Onesky for mainland China.

Negative

• Revenue decreased by 76% from the previous year.
• Gross margins declined from 91% to 60%.
• Adjusted EBITDA worsened to $(2.0) million from $(1.0) million year-over-year.

Company to Host Conference Call Today at 4:30pm ET

SARASOTA, Fla., May 16, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the first quarter ended March 31, 2022 and provided a business update.

Recent Operational Highlights

• The three INVO Centers in Birmingham, Alabama, Atlanta, Georgia, and Monterrey, Mexico experienced a 40% increase in patient inquiries and consultations compared to the 4^th quarter of 2021. This, in part, is the result of our locally targeted marketing efforts and is a positive indicator for potential treatment cycle growth in the coming periods.
• Announced plans to open additional INVO Centers in Tampa, Florida, and Kansas City, Missouri, in addition to the previously announced planned clinic in the San Francisco Bay Area.
• Signed an exclusive distribution agreement with Onesky Holdings Limited ("Onesky") for mainland China (excludes Hong Kong, Macau and Taiwan). The exclusivity is subject to minimum annual purchase amounts over a 5-year term starting upon product registration, the cost of which is to be borne by Onesky.
• Processed initial product orders from direct sales to U.S. IVF clinics and engaged with approximately 80 clinics, including both new relationships and those already trained on the INVOcell and IVC by Ferring.
• Received product orders from our Spain, Pakistan and Nigeria partnerships.

Management Commentary

"We are pleased with the progress at our INVO Centers in Birmingham, Atlanta and Monterrey," commented Steve Shum, CEO of INVO. "In the first quarter, we witnessed significantly increased patient flow at each center, which we believe will contribute to growing treatment cycles in the coming periods. Based on the typical timeframe it takes from patient inquiry, to consultation, to initial diagnostic testing, to addressing patient-specific timing issues, and to ultimately completing a treatment cycle, the timeframe between initial patient contact to cycle completion can range from 2 to 4 months or longer.  We were also pleased to see increased treatment cycles in the first quarter, which largely represented patients that began this process in the prior quarter.  With respect to our INVO Center expansion plans, our development team is making solid progress on identifying additional suitable locations. As our INVO Center activities expand and demonstrate positive results, we expect to have greater leverage in securing favorable terms both for landlord buildout contributions and for equipment and other leasing options. We are targeting these opportunities to cover a growing portion of our INVO Center start-up costs, and believe that, in time, they could fund over 50% of these expenses. We were also pleased with the order flow from our U.S. distribution business along with several international market distributors, and we expect this will continue to expand throughout the year."

"We remain enthusiastic about our multi-channel approach to commercializing INVOcell," continued Shum. "Our INVO Center model allows us to capture a significantly larger percentage of the per-cycle IVC procedure revenue enabled by the INVOcell and provides attractive economics for our shareholders, medical practitioner partners and patients alike. Our international distribution allows us to efficiently expand global adoption and accelerates our efforts to address the fertility industry's biggest challenges of cost and capacity. We look forward to continued strength in both channels going forward."

Financial Results

Revenue for the three months ended March 31, 2022, was approximately $0.2 million compared to approximately $0.7 million for the three months ended March 31, 2021. Of the $0.2 million in revenue for 2022, $0.1 was related to clinic revenue from the consolidated Atlanta JV. The decrease of approximately $0.5 million, or approximately 76%, from the first quarter of the prior year was related to a one-time bulk order from Ferring in the previous year that was made to meet calendar year 2020 minimum purchase commitments in the Ferring Agreement.

Gross margins were approximately 60% and 91% for the three months ended March 31, 2022, and 2021, respectively. The decrease in gross margin reflects the lack of Ferring license revenue in the first quarter compared to last year, as well as the inclusion of consolidated INVO Center cost of goods sold expenses.

Selling, general and administrative expenses for the three months ended March 31, 2022, were approximately $2.6 million compared to approximately $2.1 million for the three months ended March 31, 2021. The increase was primarily the result of approximately $0.2 million in increased expenses related to the operations of the consolidated Atlanta JV, $0.2 million in increased personnel expenses, and $0.1 million in marketing activities. We also incurred approximately $0.7 million of non-cash, stock-based compensation expense in the period, compared to $0.6 million for the same period in the prior year.

We continue to make progress in our 5-day label expansion efforts. R&D expenses were approximately $0.1 million and $0.07 million for the three months ended March 31, 2022, and March 31, 2021, respectively.

Loss from equity investments for the three months ended March 31, 2022, was approximately $0.07 million compared to $0.0 for the three months ended March 31, 2021. The increase in loss is due to the investments in Alabama and Mexico JV's, which became operational in the second half of 2021.

Interest expense and financing fees were approximately $0.1 thousand for the three months ended March 31, 2022, compared to approximately $0.9 million for the three months ended March 31, 2021.

Adjusted EBITDA (see Adjusted EBITDA Table) for the three months ended March 31, 2022, was $(2.0) million, which included $0.2 million loss attributable to our joint ventures, compared to adjusted EBITDA of $(1.0) million for the quarter ended March 31, 2021.

As of March 31, 2022, the Company had approximately $3.8 million in cash.

Use of Non-GAAP Measure

Adjusted EBITDA is a non-GAAP measure. This measure is not intended to be a substitute for those financial measures reported in accordance with GAAP. Adjusted EBITDA has been included because management believes that, when considered together with the GAAP figures, it provides meaningful information related to our operating performance and liquidity and can enhance an overall understanding of financial results and trends. Adjusted EBITDA may be calculated by us differently than other companies that disclose measures with the same or similar terms. See our attached financials for a reconciliation of this non-GAAP measure to the nearest GAAP measure.

Conference Call Details

INVO has scheduled a conference call for Monday, May 16, 2022, at 4:30 pm ET (1:30 pm PT) to review these results and recent events. Interested parties can access the conference call by dialing (833) 756-0861 or (412) 317-5751 or can listen via a live Internet webcast at https://app.webinar.net/6XQVP1XJjRA, which is also available in the Investor Relations section of the Company's website at https://www.invobioscience.com/investors/. A teleconference replay of the call will be available through May 23, 2022, at (877) 344-7529 or (412) 317-0088, confirmation #4725753. A webcast replay will be available in the Investor Relations section of the Company's website at https://www.invobioscience.com/investors/ for 90 days.

About INVO Bioscience

We are a commercial-stage fertility company dedicated to expanding the assisted reproductive technology ("ART") marketplace by making fertility care accessible and inclusive to people around the world. Our primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. Our flagship product is INVOcell®, a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as "IVC", provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional in vitro fertilization ("IVF") and is a significantly more effective treatment than intrauterine insemination ("IUI"). Our commercialization strategy is focused on the opening of dedicated "INVO Centers" offering the INVOcell® and IVC procedure (with three centers in North America now operational), in addition to continuing to distribute and sell our technology solution into existing fertility clinics. For more information, please visit www.invobio.com.

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

 

INVO BIOSCIENCE, INC.
CONSOLIDATED BALANCE SHEETS
		March 31, 2022			December 31, 2021
ASSETS
Current assets
Cash	$	3,839,862		$	5,684,871
Accounts receivable		58,720			50,470
Inventory		294,631			287,773
Prepaid expenses and other current assets		228,178			282,751
Total current assets		4,421,391			6,305,865
Property and equipment, net		491,995			501,436
Intangible assets, net		132,551			132,093
Lease right of use		1,980,153			2,037,052
Investment in joint ventures		1,494,143			1,489,934
Total assets	$	8,520,233		$	10,466,380
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable and accrued liabilities	$	462,211		$	443,422
Accrued compensation		391,877			581,689
Deferred revenue, current portion		5,793			5,900
Lease liability, current portion		224,361			221,993
Total current liabilities		1,084,242			1,253,004
Lease liability, net of current portion		1,844,784			1,901,557
Deferred tax liability		1,139			1,139
Total liabilities		2,930,165			3,155,700
Stockholders' equity
Common Stock, $.0001 par value; 125,000,000 shares authorized; 12,096,798 and 11,929,147 issued and outstanding as of March 31, 2022 and December 31, 2021, respectively		1,210			1,193
Additional paid-in capital		47,254,192			46,200,509
Accumulated deficit		(41,665,334)			(38,891,022)
Total equity		5,590,068			7,310,680
Total liabilities and stockholders' equity	$	8,520,233		$	10,466,380

 

INVO BIOSCIENCE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
		For the Three Months Ended March 31,
			2022			2021
Revenue:
Product revenue		$	56,750		$	505,952
Clinic revenue			105,848			-
License revenue			-			178,571
Total revenue			162,598			684,523
Cost of goods sold:
Production costs			57,533			60,314
Depreciation			7,428			2,431
Total cost of goods sold			64,961			62,745
Gross profit			97,637			621,778
Operating expenses
Selling, general and administrative			2,694,395			2,115,303
Research and development			104,180			66,267
Total operating expenses			2,798,575			2,181,570
Loss from operations			(2,700,938)			(1,559,792)
Other income (expense):
Loss from equity method joint ventures			(71,117)			-
Interest income			225			2,013
Interest expense			(1,456)			(895,226)
Foreign currency exchange loss			(1,026)			(464)
Total other expense			(73,374)			(893,677)
Net loss		$	(2,774,312)		$	(2,453,469)
Net loss per common share:
Basic		$	(0.23)		$	(0.25)
Diluted		$	(0.23)		$	(0.25)
Weighted average number of common shares outstanding:
Basic			12,050,696			9,888,025
Diluted			12,050,696			9,888,025

 

ADJUSTED EBITDA
				Three Months Ended
				March 31
				2022		2021
Net loss				$ (2,774,312)		$ (2,453,469)
		Interest expense		1,231		35,071
		Foreign currency exchange loss		1,026		464
		Stock-based compensation		310,212		192,064
		Stock option expense		428,488		376,523
		Amortization of debt discount		-		860,155
		Depreciation and amortization		15,547		8,654
Adjusted EBITDA				$ (2,017,808)		$     (980,538)
		Loss from equity method JV		$          71,117		$                   -
		Loss from consolidated JV (less depreciation)		178,697		-
Adjusted EBITDA for INVO corporate			#	$ (1,767,994)		$     (980,538)

 

INVO Center RESULTS
The following tables summarize the combined financial information of our consolidated and equity method joint venture INVO Centers:
					For the Three Months Ended March 31,
					2022		2021
Statements of operations:
Operating revenue					$             275,683		$                                 -
Operating expenses					(572,965)		-
Net income					$           (297,282)		$                                 -
					March 31, 2022		December 31, 2021
Balance sheets:
Current assets					$             696,237		$                     660,877
Long-term assets					2,170,824		2,374,471
Current liabilities					(583,453)		(585,226)
Long-term liabilities					(605,337)		(743,972)
Net assets					$          1,678,271		$                  1,706,150

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-reports-first-quarter-2022-financial-results-301548269.html

SOURCE INVO Bioscience, Inc.

FAQ

What were INVO's Q1 2022 financial results?

INVO reported a Q1 2022 revenue of approximately $0.2 million, down 76% from $0.7 million in Q1 2021.

How did the gross margins change for INVO in Q1 2022?

Gross margins decreased to 60% in Q1 2022 from 91% in Q1 2021.

What are the key operational highlights from INVO's latest press release?

INVO experienced a 40% increase in patient inquiries and announced plans for new centers in Tampa and Kansas City.

What is INVO's cash position as of March 31, 2022?

As of March 31, 2022, INVO had approximately $3.8 million in cash.

What challenges did INVO face in Q1 2022?

INVO faced a 76% revenue decrease and a decline in gross margins, impacting financial performance.